CoChat

Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management

Open access

The DOI matches its Crossref record; 129 of the 130 references it cites were found in a registry or an index; 83 of the 116 sources its claims cite were checked for support.

Abstract

The 'Body Mass Index' (BMI) is an anachronistic and outdated ratio that is used as an internationally accepted diagnostic criterion for obesity, and to prioritise, stratify, and outcome-assess its management options. On an individual level, the BMI has the potential to mislead, including inaccuracies in cardiovascular risk assessment. Furthermore, the BMI places excessive emphasis on a reduction in overall body weight (rather than optimised body composition) and contributes towards a misunderstanding of the quiddity of obesity and a dispassionate societal perspective and response to the global obesity problem. The overall objective of this review is to provide an overview of obesity that transitions away from the BMI and towards a novel vista: viewing obesity from the perspective of the skeletal muscle (SM). We resurrect the SM as a tissue hidden in plain sight and provide an overview of the key role that the SM plays in influencing metabolic health and efficiency. We discuss the complex interlinks between the SM and the adipose tissue (AT) through key myokines and adipokines, and argue that rather than two separate tissues, the SM and AT should be considered as a single entity: the 'Adipo-Muscle Axis'. We discuss the vicious circle of sarcopenic obesity, in which aging- and obesity-related decline in SM mass contributes to a worsened metabolic status and insulin resistance, which in turn further compounds SM mass and function. We provide an overview of the approaches that can mitigate against the decline in SM mass in the context of negative energy balance, including the optimisation of dietary protein intake and resistance physical exercises, and of novel molecules in development that target the SM, which will play an important role in the future management of obesity. Finally, we argue that the Adipo-Muscle Ratio (AMR) would provide a more clinically meaningful descriptor and definition of obesity than the BMI and would help to shift our focus regarding its effective management away from merely inducing weight loss and towards optimising the AMR with proper attention to the maintenance and augmentation of SM mass and function.

Overview

CoChat Summary

## TL;DR

This narrative review argues that skeletal muscle mass and function should be central to obesity management, not just body weight or BMI. The authors propose the Adipo–Muscle Ratio (AMR) as a more clinically meaningful obesity descriptor than BMI because it would capture both adipose tissue and skeletal muscle.

## Key findings

  • Skeletal muscle is presented as a major determinant of metabolic health: it accounts for >80% of post-prandial glucose uptake and is described as the largest thermogenic organ and a key contributor to basal metabolic rate.
  • Age-related decline in skeletal muscle mass was reported to start in the third decade and become noticeable beyond age 50; sarcopenic obesity is said to affect around 11% of older adults globally, with prevalence increasing beyond age 70.
  • During sustained negative energy balance, the review states that ~25% of total body weight loss typically comes from fat-free mass, and in a review of GLP1-based therapies, fat-free mass loss was reported as 20–40% of total body weight loss, with most studies >25%.
  • In a human randomized placebo-controlled trial of bimagrumab in adults with T2D and overweight/obesity over 48 weeks, the treatment group had 20.5% fat mass reduction, 3.6% lean mass increase, 9 cm waist circumference reduction, and 0.76% HbA1c reduction.

## Methods

  • The paper is a narrative review of current literature, using PubMed.
  • Search terms included “obesity,” “metabolism,” and “skeletal muscle”; the authors included peer-reviewed articles of many types, with no publication-date restrictions and English-language only.
  • Study selection was based on the authors’ perceived clinical relevance, novelty, and relative size; the paper does not report a formal systematic search or meta-analysis.

## Limitations

  • The paper states it is a narrative review, and it explicitly says the field is “vast and goes beyond the scope of this concise review.”
  • The selection process was based on authors’ judgment rather than a predefined systematic or exhaustive protocol, which limits reproducibility and makes selection bias evident from the text.
  • The paper is largely conceptual and argumentative; where it cites studies, it does not conduct a new empirical analysis, so many claims depend on previously published work rather than original data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/metabo15020085

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The Adipo–Muscle Axis (AMA). Dotted arrows show paracrine effects of myokines and adipokines on the AT and SM, respectively; solid curved arrows show systemic endocrine effects via the vasculature; and solid straight arrows show effects on Ins R sensitivity, glucose, and amino acid handling within the SM. AA: amino acids; Adipo R1: receptor for adiponectin; AMPK: AMP-activated protein kinase; AT: adipose tissue; IL-15: interleukin-15; Ins R: insulin receptor; IS: insulin signalling; mTORC1: Mammalian Target of Rapamycin Complex 1; SM: skeletal muscle; UCP1: uncoupling protein 1; V: vasculature.
Figure 1 The Adipo–Muscle Axis (AMA). Dotted arrows show paracrine effects of myokines and adipokines on the AT and SM, respectively; solid curved arrows show systemic endocrine effects via the vasculature; and solid straight arrows show effects on Ins R sensitivity, glucose, and amino acid handling within the SM. AA: amino acids; Adipo R1: receptor for adiponectin; AMPK: AMP-activated protein kinase; AT: adipose tissue; IL-15: interleukin-15; Ins R: insulin receptor; IS: insulin signalling; mTORC1: Mammalian Target of Rapamycin Complex 1; SM: skeletal muscle; UCP1: uncoupling protein 1; V: vasculature.CC BY · PubMed Central

Verification

Claims the paper makes

66 Valid · 2 Not valid · 16 Not checked · 37 Own results and interpretations

53 more claims · 32 with their cited sources checked

Create a free account to see all 121 claims and to verify the 10 references still open.

See all claims — free account
  • It may state two separate claims as one. 50
  • Probably not a substantial claim. 26

Create a free account to see these claims.

Citations

Cites

Show all 129 references

Cited by

See all 19

Metadata

Authors
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O.
Affiliations
  • University Hospital Coventry (GB)
  • Helmholtz Munich (DE)
Corresponding author
Weickert, Martin O.
Venue
Metabolites
Publisher
MDPI AG
Published
2025-02-01
Volume
15
Issue
2
Pages
85
ISSN
2218-1989 (ISSN-L)
OpenAlex
W4407141913
Cited by
19
References
130
Citations by year
2026: 13 · 2025: 6
FWCI
2.46
Type
journal article
Language
en
Open access
Locations
  • Metabolites (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Warwick Research Archive Portal (University of Warwick) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
Keywords
obesity, skeletal muscle mass, myokines, adipokines, sarcopenic obesity, insulin resistance, dietary protein, resistance training, negative energy balance, obesity treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management. https://app.cochat.ai/papers/10.3390/metabo15020085
The paper
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2025). Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management. Metabolites. https://doi.org/10.3390/metabo15020085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.